Computational Framework for Multi-Target Cancer Pathway Convergence
Bibliographic record
Abstract
【THE PROBLEM】 Cancer drug development has a 99.6% failure rate, with only 3.4% of drugs progressing from Phase I to FDA approval. Single-target therapies consistently fail because cancer cells activate compensatory pathways when one target is blocked. ◆ 【KEY INSIGHT】 Despite genetic heterogeneity across thousands of cancer mutations, all cancers converge on 6 universal downstream pathways: • (1) Translation/Ribosome Biogenesis (NOLC1-regulated) • (2) Nucleotide Synthesis (purine/pyrimidine) • (3) Mitochondrial Reprogramming (ATP production) • (4) One-Carbon Metabolism (methyl donors) • (5) DNA Damage Response (genomic stability) • (6) Metabolic Plasticity (survival under stress). Analysis of 38 independent datasets (TCGA, GEO, ICGC) covering 33 cancer types and 11,012+ patients confirms these pathways are enriched in 10-12 of 12 major cancer types (83-100% convergence). ◆ 【COMPUTATIONAL FRAMEWORK】 Multi-target botanical combinations targeting all 6 pathways simultaneously through 14 compounds with quantified IC50 values, blood-brain barrier penetration data, and established safety profiles. Mathematical modeling predicts 60-70% net therapeutic efficacy when all pathways are blocked simultaneously, compared to 14-20% for monotherapy, representing 3-5× superiority through network amplification effects. ◆ 【HISTORICAL PRECEDENT】 Multi-drug combinations have transformed treatment outcomes: HIV HAART (50-100× mortality reduction), TB multi-drug therapy (cure vs. death), cancer ABVD for Hodgkin lymphoma (5-8× response improvement). ◆ 【METHODOLOGY】 Systematic computational analysis of cancer genomics datasets, pathway enrichment analysis (GSEA, Reactome, KEGG), compound mechanism verification with IC50 values and clinical evidence, pharmacokinetic modeling for bioavailability and CYP450 interactions, and mathematical framework for synergy coefficient derivation. ◆ 【CRITICAL LIMITATION】 Zero experimental validation. This is a computational hypothesis requiring Phase I-IV trials before clinical use. All projections are evidence-based but not empirically confirmed. Keywords: Cancer, Computational oncology, Multi-target therapy, Pathway convergence, NOLC1, Drug discovery, Systems biology, Therapeutics
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.009 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".